SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 63.99+4.7%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Aloner6/6/2025 9:11:15 PM
2 Recommendations

Recommended By
Lance Bredvold
OldAIMGuy

   of 52153
 
IBRX is up more than 50% over the last 30 days and still 50% below it's 52 week high. The FDA approved their drug ANKTIVA, for NMIBC, the only drug for the treatment of Bladder Cancer, with a 80% success rate, in December. They were just approved to treat Lymphopenia for Pancreatic Cancer with the same drug. They went with Trump to the Middle East and licensed their drug to the Saudi's with Trump in the room and approving the deal. Strong balance sheet, strong quarterly report. Book value is currently $2.6B. The number of new patients with NMIBC in the US alone is 61,000 per year, the fourth leading cause of Cancer in Men. Now there is a treatment.
Conduct your own due diligence, but you should do it before they get bought out.

immunitybio.com

And speaking of Bladders, UCLA just accomplished the first ever Bladder Transplant on May 4th.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News